Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sinopharm Tech HoldingsHKSE:08156 -2.50%27 Piotroski F-Score is 5 as of Aug. 24, 2026, which is 67% above its 10-year median of 3.00. GuruFocus rates HKSE:08156 with a GF Score™ of 27/100 and a GF Value™ of HK$0.06 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 2,741 Software companies, Sinopharm Tech Holdings ranks better than 60.05% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Sinopharm Tech Holdings has an F-score of 5 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Sinopharm Tech Holdings's Piotroski F-Score or its related term are showing as below:
HKSE:08156'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 3 Max: 6
Current: 5
During the past 13 years, the highest Piotroski F-Score of Sinopharm Tech Holdings was 6. The lowest was 2. And the median was 3.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Sinopharm Tech Holdings Piotroski F-Score Related Terms
Sinopharm Tech Holdings Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Sinopharm Tech Holdings's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:08156 vs QH, SHOP, UBER: Piotroski F-Score Comparison
For the Software - Application subindustry, Sinopharm Tech Holdings's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Tech Holdings Piotroski F-Score vs Software Industry
For the Software industry and Technology sector, Sinopharm Tech Holdings's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Sinopharm Tech Holdings's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Sinopharm Tech Holdings's current Net Income (TTM) was -0.87.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Sinopharm Tech Holdings's current Cash Flow from Operations (TTM) was -5.70.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Sinopharm Tech Holdings's return on assets of this year was -0.01948753. Sinopharm Tech Holdings's return on assets of last year was -0.58831611.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Sinopharm Tech Holdings's gearing of this year was 0. Sinopharm Tech Holdings's gearing of last year was 0.0167496.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Sinopharm Tech Holdings's current ratio of this year was 0.71857084. Sinopharm Tech Holdings's current ratio of last year was 0.1526163.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Sinopharm Tech Holdings's number of shares in issue this year was 464.789. Sinopharm Tech Holdings's number of shares in issue last year was 183.693.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Sinopharm Tech Holdings's gross margin of this year was 0.23233148. Sinopharm Tech Holdings's gross margin of last year was 0.12159314.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Sinopharm Tech Holdings's asset turnover of this year was 1.3767813. Sinopharm Tech Holdings's asset turnover of last year was 1.23281166.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
0
+
1
+
1
+
0
+
1
+
1
=
5
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Sinopharm Tech Holdings has an F-score of 5 indicating the company's financial situation is typical for a stable company.
Sinopharm Tech Holdings (HKSE:08156) has a Piotroski F-Score of 5 as of Aug. 24, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sinopharm Tech Holdings and its competitors. This is 67% above median its historical median of 3.00. Over the past decade, Sinopharm Tech Holdings' Piotroski F-Score has ranged from 2.00 to 6.00. According to the industry distribution chart, Sinopharm Tech Holdings ranks #1095 out of 2741 companies in the Software industry, placing it in the top 39.9%.
Is Sinopharm Tech Holdings' Piotroski F-Score too high?
Sinopharm Tech Holdings' current Piotroski F-Score of 5 is 67% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 6.00. The Software industry median Piotroski F-Score is 5.00. Sinopharm Tech Holdings' value of 5 is 0% at this industry median. Based on the distribution chart, Sinopharm Tech Holdings ranks #1095 out of 2741 companies in the Software industry, which is above the industry midpoint. Overall, Sinopharm Tech Holdings has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Tech Holdings' Piotroski F-Score compare to QH and SHOP?
According to the Software industry distribution chart, Sinopharm Tech Holdings ranks #1095 out of 2741 companies for Piotroski F-Score. This puts Sinopharm Tech Holdings in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Sinopharm Tech Holdings' value of 5 is 0% at this benchmark. Historically, Sinopharm Tech Holdings' own Piotroski F-Score has ranged from 2.00 to 6.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, Sinopharm Tech Holdings has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Software company?
The median Piotroski F-Score among Software companies is 5.00, based on 2,741 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Tech Holdings's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sinopharm Tech Holdings and its competitors. For the Software industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Tech Holdings's current Piotroski F-Score is 5, which is 67% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Tech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Tech Holdings (HKSE:08156) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.06, compared to a current price of HK$0.16 — trading 160% above its estimated fair value. The current Piotroski F-Score is 5, which is 67% above median its 10-year median of 3.00 and 0% at the Software industry median of 5.00. Sinopharm Tech Holdings' overall GF Score™ is 27/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Sinopharm Tech Holdings (HKSE:08156), the current Piotroski F-Score is 5 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Tech Holdings (HKSE:08156) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Tech Holdings stock appears to be overvalued.
The current stock price of HK$0.16 is trading 160% above its estimated GF Value™ of HK$0.06.
GuruFocus considers Sinopharm Tech Holdings to be Significantly Overvalued.
Key valuation signals for HKSE:08156:
Piotroski F-Score: 5 (67% above median its 10-year median of 3.00)
GF Value™: HK$0.06 vs. price of HK$0.16 (160% above fair value)
Industry Position: 0% at the Software median (#1095 of 2741)
No single metric tells the full story. See the HKSE:08156 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sinopharm Tech Holdings Ltd is an investment holding company operating through three segments: Internet Plus services, Supply Chain services, and Manufacturing and distribution of personal protective equipment. The company generates the majority of its revenue from the Supply Chain services segment, which includes supply chain management, data analysis, and trading of medical and related products. Geographically, it operates in Hong Kong and the People's Republic of China (PRC), with the majority of its revenue coming from the PRC.
27GF Score
Get the complete analysis for HKSE:08156
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08156 has been successfully added to your 
